SCHEMBL24099285

SCHEMBL24099285

CCOC(=O)/C=C/c1ccc2nc(C)n(-c3c(C)cccc3C)c(=O)c2c1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
IDO1 P14902 2/20 0.41
TDO2 P48775 1/20 0.41
ALOX15 P16050 1/20 0.39
P2RY12 Q9H244 1/20 0.38
ESR1 P03372 1/20 0.36
CCNC P24863 3/20 0.36
CDK8 P49336 3/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
KCNH2 Q12809 2/20 0.35
HRH3 Q9Y5N1 2/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35
CA14 Q9ULX7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28971440 1.00 HDAC1 (0.42) HDAC1HDAC8HDAC6IDO1TDO2
SCHEMBL24098560 0.83 HDAC1 (0.61) HDAC1HDAC8HDAC6CYP3A4
SCHEMBL24099413 0.83 IDO1 (0.47) HDAC1HDAC8HDAC6IDO1TDO2
SCHEMBL28971429 0.83 IDO1 (0.47) HDAC1HDAC8HDAC6IDO1TDO2
SCHEMBL28971434 0.82 IDO1 (0.45) HDAC1HDAC8HDAC6IDO1TDO2
SCHEMBL25889700 0.82 IDO1 (0.45) HDAC1HDAC8HDAC6IDO1TDO2
SCHEMBL24098880 0.79 IDO1 (0.43) HDAC1HDAC8HDAC6IDO1TDO2
SCHEMBL28971447 0.79 IDO1 (0.43) HDAC1HDAC8HDAC6IDO1TDO2
SCHEMBL24099276 0.77 POLB (0.41) HDAC1HDAC8HDAC6KCNH2HRH3
SCHEMBL24098960 0.76 IDO1 (0.50) HDAC1HDAC8HDAC6IDO1TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4161908-B1 QUINAZOLINE DERIVATIVES USEFUL AS SELECTIVE HDAC6 INHIBITORS ANNJI PHARM CO LTD (TW) 2026-04-01 EP disclosed
US-20230212129-A1 QUINAZOLINE DERIVATIVES USEFUL AS SELECTIVE HDAC6 INHIBITORS Annji Pharmaceutical Co., Ltd. (TW) 2023-07-06 US disclosed
US-20230212129-A1 QUINAZOLINE DERIVATIVES USEFUL AS SELECTIVE HDAC6 INHIBITORS Annji Pharmaceutical Co., Ltd. (TW) 2023-07-06 US disclosed
EP-4161908-A1 QUINAZOLINE DERIVATIVES USEFUL AS SELECTIVE HDAC6 INHIBITORS Annji Pharmaceutical Co., Ltd. (TW) 2023-04-12 EP disclosed
WO-2021252475-A1 QUINAZOLINE DERIVATIVES USEFUL AS SELECTIVE HDAC6 INHIBITORS Annji Pharmaceutical Co., Ltd. (TW) 2021-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212129-A1 QUINAZOLINE DERIVATIVES USEFUL AS SELECTIVE HDAC6 INHIBITORS HDAC6, HDAC1, HDAC5 HDAC1 2/4885HDAC8 16/4885HDAC6 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.